Grant ID RP240288
Awarded On February 21, 2024
Title Epigenetic mechanism and targeting during response to BRAFi/anti-EGFR therapy in BRAF-mutant colorectal cancers
Program Academic Research
Award Mechanism Individual Investigator
Institution/Organization The University of Texas M.D. Anderson Cancer Center
Principal Investigator/Program Director Scott Kopetz
Cancer Sites Colorectal
Contracted Amount $1,043,909*

*Pending contract negotiation

Lay Summary

Colorectal cancer (CRC) is the second leading cause of cancer-related deaths in the United States with an estimated 52,550 deaths in 2023. Approximately, 5-10% of metastatic colorectal cancer (mCRC) patients have BRAF mutations, which is associated with extremely poor prognosis and dismal survival. BRAFV600E-mutated CRC harbors significant epigenetic mutations; however, the role of epigenome in tumor progression and utilization of epigenetic drugs in these patients are not yet understood. Evaluation of specific epigenetic proteins could be targets for therapy in these cancers revealed BRD2 as an epigenetic marker that may sensitize cell lines to BRAF and EGFR inhibitor. Moreover, our prelimi...

Read More